Viral therapy for peripheral T-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests an experimental virus therapy given through a vein for people with a type of lymphoma called peripheral T-cell lymphoma that has come back or not responded to treatment. The virus is designed to infect and destroy cancer cells. Some patients may also receive another drug called cemiplimab as part of a combination group.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have peripheral T-cell lymphoma (a type of lymphoma) that has returned or not improved after treatment.
- You need to have at least one tumor that can be seen on a scan (at least 2 cm in size) or a certain number of lymphoma cells in your blood.
- Your liver and kidney function must be within safe limits based on recent blood tests.
- You cannot have active infections like tuberculosis or hepatitis, or be HIV positive.
- You must be willing to use effective birth control if you are of childbearing age or have a partner who is.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination therapy with tazemetostat for people whose peripheral T-cell lymphoma has come back or hasn't responded to previous treatment. The goal is to see if this drug combination can help shrink tumors or slow the disease.
This early-phase trial tests a personalized-style vaccine (called VSV-hIFNβ-NIS) given alone or with other cancer-fighting medicines, including drugs that help the immune system attack. It is designed for people with certain relapsed or hard-to-treat multiple myeloma, acute myeloid leukemia, or lymphomas, to see if the treatment can shrink tumors and improve outcomes.
This trial tests a new combination of targeted drugs called ViPOR for people with aggressive B-cell lymphoma that has come back or not responded to previous treatment. The goal is to see if this treatment can help when standard therapies haven't worked.
This trial tests a special T-cell treatment (LB-DTK-MV) for people with virus infections (CMV, BKV, EBV) that did not get better with standard medicines. It is for patients who had a stem cell transplant or certain cancer therapies like CAR-T or bispecific antibodies.
This trial uses a modified virus to deliver CAR-T cells directly into tumors, aiming to treat B-cell lymphoma that has come back or not responded to other treatments. It may be an option if your lymphoma is CD19-positive and you've tried at least two prior therapies.
This trial tests a treatment using specially grown T-cells (a type of immune cell) to fight certain viruses that won't go away with standard medicines. It is for people who have had a stem cell or organ transplant, or who have a weak immune system, and who are struggling with adenovirus, CMV, or EBV infections.
Hear when a new Peripheral T Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.